BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32407947)

  • 1. Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial.
    Thompson CP; Silvers S; Shapiro MA
    Ann Allergy Asthma Immunol; 2020 Sep; 125(3):311-318.e2. PubMed ID: 32407947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.
    Hylander T; Larsson O; Petersson-Westin U; Eriksson M; Kumlien Georén S; Winqvist O; Cardell LO
    Respir Res; 2016 Jan; 17():10. PubMed ID: 26817454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
    Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis.
    Terada T; Omura S; Kikuoka Y; Suzuki M; Inaka Y; Inui T; Matsuda M; Nabe T; Kawata R
    Rhinology; 2020 Jun; 58(3):241-247. PubMed ID: 32091032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study.
    Murakami D; Sawatsubashi M; Kikkawa S; Ejima M; Saito A; Kato A; Komune S
    Auris Nasus Larynx; 2016 Feb; 43(1):50-5. PubMed ID: 26197940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis.
    Horiguchi S; Okamoto Y; Yonekura S; Okawa T; Yamamoto H; Kunii N; Sakurai D; Fujimura T; Nakazawa K; Yasueda H
    Int Arch Allergy Immunol; 2008; 146(1):76-84. PubMed ID: 18087165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet.
    Gotoh M; Yonekura S; Imai T; Kaneko S; Horikawa E; Konno A; Okamoto Y; Okubo K
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1287-1297.e8. PubMed ID: 30537561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
    Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
    J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis.
    Andrews CP; Ratner PH; Ehler BR; Brooks EG; Pollock BH; Ramirez DA; Jacobs RL
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):9-13. PubMed ID: 23806453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis.
    Okamoto Y; Okubo K; Yonekura S; Hashiguchi K; Goto M; Otsuka T; Murata T; Nakao Y; Kanazawa C; Nagakura H; Okawa T; Nakano K; Hisamitsu M; Kaneko S; Konno A
    Int Arch Allergy Immunol; 2015; 166(3):177-88. PubMed ID: 25895909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a prospective, randomized, open-label study.
    Murakami D; Sawatsubashi M; Kikkawa S; Ejima M; Saito A; Kato A; Komune S
    Allergol Int; 2015 Apr; 64(2):161-8. PubMed ID: 25838092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.
    Ahlbeck L; Ahlberg E; Stuivers L; Björkander J; Nyström U; Retsas P; Govindaraj D; Jenmalm MC; Duchén K
    Clin Exp Allergy; 2023 Aug; 53(8):809-820. PubMed ID: 37013723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lowered effectiveness of immunotherapy for cypress pollinosis by using Japanese cedar pollen extract].
    Horiguchi S; Okamoto Y; Yonekura S; Okawa T; Kunii N; Yamamoto H; Sakurai D; Hanazawa T
    Arerugi; 2008 May; 57(5):558-61. PubMed ID: 18520178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.
    Mösges R; Bachert C; Panzner P; Calderon MA; Haazen L; Pirotton S; Wathelet N; Durham SR; Bonny MA; Legon T; von Frenckell R; Pfaar O; Shamji MH
    Allergy; 2018 Sep; 73(9):1842-1850. PubMed ID: 29512827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
    Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
    Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.